-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AstraZeneca has announced that its COVID-19 candidate vaccine, AZD1222, in partnership with Oxford University, has shown potential for both the elderly and the young.
vaccines induced the production of protective antibodies and T-cell responses in older adults.
: Since the new coronavirus pandemic, older people have been determined to be at higher risk of hospitalization and death from COVID-19 than young people.
finding vaccines that work for older people is also more challenging, according to the U.S. Centers for Disease Control and Prevention (CDC).
because older people are at higher risk of serious complications from infectious diseases, and immunity decreases with age.
AstraZeneta's vaccine has fewer adverse reactions in older adults than inducing an immune response, Reuters reported.
, an AZ spokesman, also told Reuters: "It is encouraging that older people and young people have similar immune responses.
AZ said Friday that the U.S. Food and Drug Administration (FDA) has authorized the restart of its Phase 3 COVID-19 vaccine trial.
clinical trial was suspended in September after participants experienced serious adverse events.
has been revived around the world, including in the UNITED States, Britain, Brazil, South Africa and Japan.
